Chethan Ramamurthy

6PUBLICATIONS
34CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 19, 2026
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Jan 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.

Petros Grivas, Damien Pouessel, Chandler H Park

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

Pageof 1

Frequent Collaborators

4 joint publications

Daniel P Petrylak

2 joint publications

Jennifer Stuart

2 joint publications

Matthew I Milowsky

2 joint publications

Christopher J Hoimes